Published in Drug Metab Pharmacokinet on January 01, 2008
Pharmacokinetic drug interaction profile of omeprazole with adverse consequences and clinical risk management. Ther Clin Risk Manag (2013) 0.96
Pyrosequencing to identify homogeneous phenomenon when using recipients/donors with different CYP3A5*3 genotypes in living donor liver transplantation. PLoS One (2013) 0.86
Continuous cell supply from a Sox9-expressing progenitor zone in adult liver, exocrine pancreas and intestine. Nat Genet (2010) 6.81
Nonalcoholic steatohepatitis in donors for living donor liver transplantation. Transplantation (2007) 2.25
Expression of OATP1B3 determines uptake of Gd-EOB-DTPA in hepatocellular carcinoma. J Gastroenterol (2009) 2.23
Living donor liver transplantation: the Asian perspective. Transplantation (2014) 2.13
Impact of human leukocyte antigen mismatching on outcomes of living donor liver transplantation for primary biliary cirrhosis. Liver Transpl (2007) 2.09
Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. Biochem Pharmacol (2007) 2.05
Portal pressure <15 mm Hg is a key for successful adult living donor liver transplantation utilizing smaller grafts than before. Liver Transpl (2010) 2.02
Successful autologous peripheral blood stem cell transplantation with a double-conditioning regimen for recurrent hepatoblastoma after liver transplantation. Pediatr Transplant (2008) 1.99
Perioperative changes in nutritional parameters and impact of graft size in patients undergoing adult living donor liver transplantation. Liver Transpl (2014) 1.97
Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. Drug Metab Pharmacokinet (2005) 1.96
Serum-derived hepatitis C virus infectivity in interferon regulatory factor-7-suppressed human primary hepatocytes. J Hepatol (2006) 1.89
Early-stage hepatocellular carcinoma: radiofrequency ablation combined with chemoembolization versus hepatectomy. Radiology (2008) 1.86
Gene expression levels and immunolocalization of organic ion transporters in the human kidney. J Am Soc Nephrol (2002) 1.85
Does a positive lymphocyte cross-match contraindicate living-donor liver transplantation? Surgery (2010) 1.82
UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients. Int J Clin Oncol (2009) 1.82
Single center experience of 39 patients with preoperative portal vein thrombosis among 404 adult living donor liver transplantations. Liver Transpl (2006) 1.81
Identification and functional characterization of a new human kidney-specific H+/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2. J Am Soc Nephrol (2006) 1.80
Hepatic stellate cells secrete angiopoietin 1 that induces angiogenesis in liver fibrosis. Gastroenterology (2008) 1.79
Fibroblast growth factor (FGF)-23 inhibits renal phosphate reabsorption by activation of the mitogen-activated protein kinase pathway. J Biol Chem (2002) 1.79
Donor-dependent variations in hepatic differentiation from human-induced pluripotent stem cells. Proc Natl Acad Sci U S A (2012) 1.78
Auxiliary partial orthotopic living donor liver transplantation: Kyoto University experience. Am J Transplant (2005) 1.70
SLCO4C1 transporter eliminates uremic toxins and attenuates hypertension and renal inflammation. J Am Soc Nephrol (2009) 1.70
Progressive graft fibrosis and donor-specific human leukocyte antigen antibodies in pediatric late liver allografts. Liver Transpl (2012) 1.67
Outcomes after living donor liver transplantation for acute liver failure in Japan: results of a nationwide survey. Liver Transpl (2012) 1.64
Left-sided grafts for living-donor liver transplantation and split grafts for deceased-donor liver transplantation: their impact on long-term survival. Clin Res Hepatol Gastroenterol (2011) 1.63
Living donor liver transplantation with reduced monosegments for neonates and small infants. Transplantation (2007) 1.61
The presence of Foxp3 expressing T cells within grafts of tolerant human liver transplant recipients. Transplantation (2008) 1.61
Impact of quality as well as quantity of skeletal muscle on outcomes after liver transplantation. Liver Transpl (2014) 1.58
Comprehensive and innovative techniques for liver transplantation in rats: a surgical guide. World J Gastroenterol (2010) 1.57
Plasma concentrations and importance of High Mobility Group Box protein in the prognosis of organ failure in patients with disseminated intravascular coagulation. Thromb Haemost (2005) 1.55
Targeted disruption of the multidrug and toxin extrusion 1 (mate1) gene in mice reduces renal secretion of metformin. Mol Pharmacol (2009) 1.53
Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther (2006) 1.52
CHOP deficiency attenuates cholestasis-induced liver fibrosis by reduction of hepatocyte injury. Am J Physiol Gastrointest Liver Physiol (2008) 1.52
Acute humoral rejection and C4d immunostaining in ABO blood type-incompatible liver transplantation. Liver Transpl (2006) 1.52
Risk factors for alcohol relapse after liver transplantation for alcoholic cirrhosis in Japan. Liver Transpl (2014) 1.52
Donor morbidity in right and left hemiliver living donor liver transplantation: the impact of graft selection and surgical innovation on donor safety. Transpl Int (2014) 1.51
Allograft steatohepatitis in progressive familial intrahepatic cholestasis type 1 after living donor liver transplantation. Liver Transpl (2009) 1.50
MicroRNA profile predicts recurrence after resection in patients with hepatocellular carcinoma within the Milan Criteria. PLoS One (2011) 1.50
Noninvasive evaluation of graft steatosis in living donor liver transplantation. Transplantation (2004) 1.49
Creatinine transport by basolateral organic cation transporter hOCT2 in the human kidney. Pharm Res (2004) 1.49
Dai-kenchu-to attenuates rat sinusoidal obstruction syndrome by inhibiting the accumulation of neutrophils in the liver. J Gastroenterol Hepatol (2009) 1.48
Factors affecting operational tolerance after pediatric living-donor liver transplantation: impact of early post-transplant events and HLA match. Transpl Int (2011) 1.48
Living donor liver transplantation as a second-line therapeutic strategy for patients with hepatocellular carcinoma. Liver Transpl (2006) 1.48
Anatomical variations and surgical strategies in right lobe living donor liver transplantation: lessons from 120 cases. Transplantation (2002) 1.48
Identification and comparative functional characterization of a new human riboflavin transporter hRFT3 expressed in the brain. J Nutr (2010) 1.47
Long-term quality of life of donors after living donor liver transplantation. Liver Transpl (2012) 1.47
Tacrolimus therapy as an alternative to thiopurines for maintaining remission in patients with refractory ulcerative colitis. J Clin Gastroenterol (2011) 1.47
Biliary complications in donors for living donor liver transplantation. Am J Gastroenterol (2008) 1.46
Pre- and perioperative factors affecting infection after living donor liver transplantation. Nutrition (2012) 1.46
Enhanced expression of enterocyte P-glycoprotein depresses cyclosporine bioavailability in a recipient of living donor liver transplantation. Liver Transpl (2003) 1.46
Changes in portal venous pressure in the early phase after living donor liver transplantation: pathogenesis and clinical implications. Transplantation (2003) 1.45
Living-donor liver transplantation with monosegments. Transplantation (2003) 1.45
A phosphodiesterase III inhibitor protects rat liver from sinusoidal obstruction syndrome through heme oxygenase-1 induction. Ann Surg (2009) 1.44
Fluorine-18 fluorodeoxyglucose positron emission tomography predicts tumor differentiation, P-glycoprotein expression, and outcome after resection in hepatocellular carcinoma. Clin Cancer Res (2007) 1.43
Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer. Cancer Chemother Pharmacol (2012) 1.43
Bone marrow-derived mesenchymal stem cells ameliorate hepatic ischemia reperfusion injury in a rat model. PLoS One (2011) 1.43
Hepatopulmonary syndrome and portopulmonary hypertension: a report of the multicenter liver transplant database. Liver Transpl (2004) 1.42
Noninvasive ventilation improves the outcome of pulmonary complications after liver resection. Intern Med (2010) 1.40
Identification and functional characterization of a novel human and rat riboflavin transporter, RFT1. Am J Physiol Cell Physiol (2008) 1.38
Is MIBG a substrate of P-glycoprotein? Eur J Nucl Med Mol Imaging (2006) 1.37
Duct-to-duct biliary reconstruction in living donor liver transplantation utilizing right lobe graft. Ann Surg (2002) 1.37